Cellestis Shareholders OK Acquisition by Qiagen | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Shareholders of Australian firm Cellestis have approved the proposed acquisition of the firm by Qiagen.

The terms of the deal, which were amended last month to increase the total amount of consideration being paid, was overwhelmingly approved by Cellestis' shareholders with 92 percent of votes in favor of the deal. Roughly 73.9 million votes were cast in favor of the amended scheme, and around 6.5 million votes were against the proposal.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."